PIM Kinase Inhibitor, PIM447, Decreases Cancer Cell Stemness And Exhibits Synergy With Cisplatin In Hepatoblastoma

Background: Current chemotherapy regimens for hepatoblastoma include platinum-based combinations that have remained virtually unchanged over the last twenty years. The overall survival for children with advanced stage or recurrent disease utilizing these regimens remains poor. We have previously shown that Proviral Integration site for Moloney murine leukemia virus (PIM) kinases act as oncoproteins promoting hepatoblastoma cell survival and the cancer stem cell phenotype, which may contribute to chemoresistance. We hypothesized that PIM inhibition utilizing …